| NCT ID | NCT04348747 |
| Title | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
| Recruitment | Not yet recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Roswell Park Cancer Institute |
| Indications | |
| Therapies |
Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod |
| Age Groups: | senior adult |